990 reports of this reaction
5.1% of all VIGABATRIN reports
#3 most reported adverse reaction
DRUG DOSE OMISSION is the #3 most commonly reported adverse reaction for VIGABATRIN, manufactured by Lundbeck Pharmaceuticals LLC. There are 990 FDA adverse event reports linking VIGABATRIN to DRUG DOSE OMISSION. This represents approximately 5.1% of all 19,478 adverse event reports for this drug.
Patients taking VIGABATRIN who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is moderately reported among VIGABATRIN users, representing a notable but not dominant share of adverse events.
In addition to drug dose omission, the following adverse reactions have been reported for VIGABATRIN:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 990 FDA reports for VIGABATRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 5.1% of all adverse event reports for VIGABATRIN, making it one of the most commonly reported side effect.
If you experience drug dose omission while taking VIGABATRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.